The toxicities associated with aromatase inhibitors (AIs) may explain the lack of overall survival improvement compared with tamoxifen, according to a study published August 22 in the Journal of The National Cancer Institute. AIs are a class of drugs used to treat breast cancer in postmenopausal women...
More...